TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Foghorn Therapeutics ( (FHTX) ).
On June 27, 2025, Foghorn Therapeutics Inc. entered into a new lease agreement for a 72,846 square foot space in Watertown, MA, to serve as its principal executive offices and for research, development, and manufacturing purposes. The lease is set to commence on July 16, 2025, with rent starting in October 2026, and includes options for extension. Concurrently, the company terminated its previous lease for 81,441 square feet in Cambridge, MA, which was originally set to expire in 2028, as part of its strategic relocation plan.
The most recent analyst rating on (FHTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.
Spark’s Take on FHTX Stock
According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.
Foghorn Therapeutics’ stock is significantly impacted by its financial distress, with persistent losses and negative equity as key concerns. Moderate technical indicators provide some bullish signals, but the poor valuation metrics, due to ongoing losses and lack of dividends, weigh heavily on the overall score.
To see Spark’s full report on FHTX stock, click here.
More about Foghorn Therapeutics
Foghorn Therapeutics Inc. operates in the biotechnology industry, focusing on the development and manufacturing of therapeutic products. The company is engaged in research and development activities, with a market focus on innovative treatments.
Average Trading Volume: 133,511
Technical Sentiment Signal: Sell
Current Market Cap: $269.8M
For an in-depth examination of FHTX stock, go to TipRanks’ Overview page.